Teva Pharmaceutical Industries Ltd. (NYSE: TEVA; TASE: TEVA) spent $3.2 million on lobbying the White House, Congress and federal agencies in January-September 2013. While this may be small change for the company, it is 40% more than it spent in the corresponding period of 2012.
Teva spent $810,000 on lobbying in the third quarter, about the same as in the preceding quarter, according to its Lobbying Report, filed under the Lobbying Disclosure Act of 1995.
Teva lobbied the House of Representatives and the Senate, as well as the US Food and Drug Administration (FDA), the Patent and Trademark Office, the US Trade Representative, and other federal agencies.
Under US law, Teva must disclose its lobbying. Israel's disclosure rules are different. An examination of the Knesset website does not mention Teva in the list of lobbyists and their clients.
The issues that Teva lobbies include bills on prescription drug abuse, drug labeling and electronic labeling proposals; access to Plan B contraceptives, counterfeit drugs: the Safeguarding America's Pharmaceuticals Act, the Pharmaceutical Quality, Security and Accountability Act, the Preserve Access to Affordable Generics Act.
Published by Globes [online], Israel business news - www.globes-online.com - on October 22, 2013
© Copyright of Globes Publisher Itonut (1983) Ltd. 2013